Leslie Lee
Family · Bolivar, TNNPI 1851591317
Payments from drug & device makers
Across 113 payments — averaging $63.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$5K
- Johnson & Johnson$443
- AbbVie$287
- Axsome Therapeutics, Inc.$222
- Neurocrine Biosciences, Inc.$197
- Otsuka America Pharmaceutical, Inc.$172
- plus $588 from 10 others
What the payments were for
- Consulting fees$3305%
- Speaking & faculty fees$4,39661%
- Travel & lodging$571%
- Food & beverage$2,27632%
- Education$1112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $5,262 |
| Johnson & Johnson(2 entities) | 23 | $443 |
| AbbVie | 12 | $287 |
| Axsome Therapeutics, Inc. | 3 | $222 |
| Neurocrine Biosciences, Inc. | 8 | $197 |
| Otsuka America Pharmaceutical, Inc. | 7 | $172 |
| Lundbeck LLC | 6 | $147 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $114 |
| Amarin Pharma, Inc. | 5 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $58 |
| Noven Therapeutics, LLC | 2 | $35 |
| Novo Nordisk | 1 | $17 |
| Amgen | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$4,726
- Auvelity$125
- VRAYLAR$115
- COBENFY$115
How this compares
$7,170 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 26 | $268,938 |
| Invega SustennaPaliperidone Palmitate | 36 | $103,510 |
| CaplytaLumateperone Tosylate | 56 | $92,562 |
| RexultiBrexpiprazole | 44 | $65,003 |
| VraylarCariprazine Hcl | 17 | $24,375 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $10,770 |
| Lurasidone Hcl | 30 | $4,930 |
| Aripiprazole | 48 | $3,536 |
| Duloxetine Hcl | 50 | $3,139 |
| Buspirone Hcl | 178 | $2,773 |
| Oxcarbazepine | 34 | $2,052 |
| Quetiapine Fumarate | 104 | $1,822 |
| Trazodone Hcl | 200 | $1,689 |
| Carbamazepine | 21 | $1,440 |
| Ziprasidone Hcl | 18 | $1,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $5,262 | $268,93826 claims |
| Johnson & JohnsonInvega Sustenna | $443 | $103,51036 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $114 | $92,56256 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $172 | $65,00344 claims |
| AbbVieVraylar | $287 | $24,37517 claims |
| Axsome Therapeutics, Inc.Auvelity | $222 | $10,77011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Bolivar
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.